GENEVA — The World Health Organization (WHO) has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, urging countries to expand access to affordable insulin and reliable blood-glucose monitoring as millions of people continue to face barriers to essential care.

Announced ahead of World Diabetes Day 2026, the recommendations are designed for use across different health systems, including low-resource communities, emergency settings and humanitarian crises. The guidance addresses a longstanding gap in global diabetes care: type 1 diabetes is often associated with childhood, but adults are also affected and require lifelong access to insulin.

WHO estimates that approximately 9.5 million people were living with type 1 diabetes worldwide in 2025, with about 500,000 additional diagnoses recorded during the year. In the condition, the body does not produce enough insulin, making daily insulin treatment essential for survival.

What The New Guidelines Recommend

WHO recommends intensified insulin treatment, generally involving several injections each day, with doses adjusted according to blood-glucose readings. Human insulin is identified as an effective option and may be particularly important where affordability is a concern. Insulin analogues may also be used when clinically appropriate and available.

The guidance also emphasizes regular monitoring. People may check glucose at home using finger-prick tests or continuous glucose monitoring sensors, while clinics can use blood tests that assess average glucose levels over recent months. Where blood-glucose testing is unavailable, WHO says urine glucose testing may be considered as an alternative, although it does not provide the same information as blood testing.

The recommendations are intended to help clinicians and health authorities develop safe, practical treatment pathways. They also underline the importance of maintaining insulin supplies and follow-up care when health services are disrupted by emergencies, displacement or financial hardship.

The Global Access Challenge

For people with type 1 diabetes, insulin is not an optional medicine. Interruptions can quickly become life-threatening. Yet access remains uneven, particularly in settings where medicines, monitoring equipment and trained health professionals are difficult to obtain or afford.

WHO says the new guidance supports its 2030 targets for universal access to affordable insulin and blood-glucose self-monitoring. Achieving those goals will require more than publishing clinical recommendations: governments will need dependable procurement systems, trained health workers, accessible diagnostic services and policies that reduce out-of-pocket costs.

The organization also encourages people living with type 1 diabetes to participate in designing and evaluating national programmes. Their experiences can help identify practical barriers that may not be visible in policy documents alone.

The guidelines do not replace individualized medical advice. Insulin type, dose and monitoring plans must be determined with qualified health professionals according to each patient’s clinical needs and circumstances. People should not change or stop prescribed insulin without medical guidance.

Source: World Health Organization — First Guidelines On Type 1 Diabetes For Adults.